<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>37(7)</volume><submitter>Valable S</submitter><pubmed_abstract>The partial pressure in oxygen remains challenging to map in the brain. Two main strategies exist to obtain surrogate measures of tissue oxygenation: the tissue saturation studied by magnetic resonance imaging (S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI) and the identification of hypoxia by a positron emission tomography (PET) biomarker with 3-[&lt;sup>18&lt;/sup>F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([&lt;sup>18&lt;/sup>F]-FMISO) as the leading radiopharmaceutical. Nonetheless, a formal validation of S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI against FMISO-PET has not been performed. The objective of our studies was to compare the two approaches in (a) the normal rat brain when the rats were submitted to hypoxemia; (b) animals implanted with four tumour types differentiated by their oxygenation. Rats were submitted to normoxic and hypoxemic conditions. For the brain tumour experiments, U87-MG, U251-MG, 9L and C6 glioma cells were orthotopically inoculated in rats. For both experiments, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI and [&lt;sup>18&lt;/sup>F]-FMISO PET were performed sequentially. Under hypoxemia conditions, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI revealed a decrease in oxygen saturation in the brain. Nonetheless, [&lt;sup>18&lt;/sup>F]-FMISO PET, pimonidazole immunohistochemistry and molecular biology were insensitive to hypoxia. Within the context of tumours, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI was able to detect hypoxia in the hypoxic models, mimicking [&lt;sup>18&lt;/sup>F]-FMISO PET with high sensitivity/specificity. Altogether, our data clearly support that, in brain pathologies, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI could be a robust and specific imaging biomarker to assess hypoxia.</pubmed_abstract><journal>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</journal><pagination>2584-2597</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5531354</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Imaging of brain oxygenation with magnetic resonance imaging: A validation with positron emission tomography in the healthy and tumoural brain.</pubmed_title><pmcid>PMC5531354</pmcid><pubmed_authors>Touzani O</pubmed_authors><pubmed_authors>Valable S</pubmed_authors><pubmed_authors>Bernaudin M</pubmed_authors><pubmed_authors>Chakhoyan A</pubmed_authors><pubmed_authors>Barbier EL</pubmed_authors><pubmed_authors>Divoux D</pubmed_authors><pubmed_authors>Durand L</pubmed_authors><pubmed_authors>Corroyer-Dulmont A</pubmed_authors><pubmed_authors>Toutain J</pubmed_authors><pubmed_authors>MacKenzie ET</pubmed_authors><pubmed_authors>Barre L</pubmed_authors><pubmed_authors>Petit E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Imaging of brain oxygenation with magnetic resonance imaging: A validation with positron emission tomography in the healthy and tumoural brain.</name><description>The partial pressure in oxygen remains challenging to map in the brain. Two main strategies exist to obtain surrogate measures of tissue oxygenation: the tissue saturation studied by magnetic resonance imaging (S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI) and the identification of hypoxia by a positron emission tomography (PET) biomarker with 3-[&lt;sup>18&lt;/sup>F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([&lt;sup>18&lt;/sup>F]-FMISO) as the leading radiopharmaceutical. Nonetheless, a formal validation of S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI against FMISO-PET has not been performed. The objective of our studies was to compare the two approaches in (a) the normal rat brain when the rats were submitted to hypoxemia; (b) animals implanted with four tumour types differentiated by their oxygenation. Rats were submitted to normoxic and hypoxemic conditions. For the brain tumour experiments, U87-MG, U251-MG, 9L and C6 glioma cells were orthotopically inoculated in rats. For both experiments, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI and [&lt;sup>18&lt;/sup>F]-FMISO PET were performed sequentially. Under hypoxemia conditions, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI revealed a decrease in oxygen saturation in the brain. Nonetheless, [&lt;sup>18&lt;/sup>F]-FMISO PET, pimonidazole immunohistochemistry and molecular biology were insensitive to hypoxia. Within the context of tumours, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI was able to detect hypoxia in the hypoxic models, mimicking [&lt;sup>18&lt;/sup>F]-FMISO PET with high sensitivity/specificity. Altogether, our data clearly support that, in brain pathologies, S&lt;sub>t&lt;/sub>O&lt;sub>2&lt;/sub>-MRI could be a robust and specific imaging biomarker to assess hypoxia.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Jul</publication><modification>2021-02-21T01:58:15Z</modification><creation>2019-03-26T23:43:12Z</creation></dates><accession>S-EPMC5531354</accession><cross_references><pubmed>27702880</pubmed><doi>10.1177/0271678X16671965</doi><doi>10.1177/0271678x16671965</doi></cross_references></HashMap>